A randomized phase ll study consisting S-1 + CDDP (SP) and Capecitabin + CDDP (XP) for adversed/metastatic gastric cancer with mesurable lesions and HER2 negative tumor (HERBIS-4A).
Phase of Trial: Phase II
Latest Information Update: 13 May 2018
At a glance
- Drugs Capecitabine (Primary) ; Cisplatin (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- Acronyms HERBIS-4A
- 20 Jan 2018 Primary endpoint (Response rate) has not been met, according to the results presented at the 2018 Gastrointestinal Cancers Symposium
- 20 Jan 2018 Results presented at the 2018 Gastrointestinal Cancers Symposium
- 30 Jun 2016 Status changed from recruiting to discontinued.